Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results
May 12, 2020 16:05 ET | Cyclacel
- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - - Following Recent Financing Cash Runway to End of 2022 - BERKELEY HEIGHTS, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results
May 05, 2020 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals logo
Cyclacel Announces Reverse Stock Split
April 14, 2020 12:30 ET | Cyclacel
BERKELEY HEIGHTS, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 26, 2020 16:05 ET | Cyclacel
– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – ...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results
November 13, 2019 16:05 ET | Cyclacel
– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference
September 23, 2019 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
September 09, 2019 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...